Researchers explored the potential impact of more than 100 risk factors on a person's risk of sudden cardiac arrest. Some of their findings were what you may expect, but others were much more surprising.

New data published in JACC represents another big win for Bayer's finerenone. The drug has previously been linked to cardiovascular benefits for patients with CKD and heart failure, but its potential across the full CKM spectrum remained a bit of a mystery.

Two of the world's leading medtech companies have been collaborating to improve patient access to CGM technology. It now looks like Medtronic and Abbott could be close to gaining FDA clearance and moving forward to the next phase of their partnership.

The advanced machine learning model tracks more than 50 different factors to make its predictions. It has already been found to be more accurate than popular prediction methods for heart disease that are currently available. 

The study's authors focused on blood pressure reductions and arterial stiffness, sharing their findings in Current Developments in Nutrition.

Researchers focused on data from nearly 78,000 adults with cardiometabolic disorders, sharing their findings at ACC.25 in Chicago.

Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.  

Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.